Telmisartan: a Different Angiotensin II Receptor Blocker Protecting a Different Population?

By Burnier M  

The Journal of International Medical Research, Vol. 37, Iss. 6, 2009-11 ,pp. : 1662-1679

Field House Publishing

Access to resources Recommend Favorite

Antiproteinuric Effect of Angiotensin-converting Enzyme Inhibitors and an Angiotensin II Receptor Blocker in Patients with Lupus Nephritis

By Kitamura N   Matsukawa Y   Takei M   Sawada S  

The Journal of International Medical Research, Vol. 37, Iss. 3, 2009-05 ,pp. : 892-898

Field House Publishing

Access to resources Recommend Favorite

Binding of the antagonist [ 3 H]candesartan to angiotensin II AT 1 receptor-tranfected Chinese hamster ovary cells

By Fierens F.   Vanderheyden P.M.L.   De Backer J.-P.   Vauquelin G.  

European Journal of Pharmacology, Vol. 367, Iss. 2, 1999-02 ,pp. : 413-422

Elsevier

Access to resources Recommend Favorite

Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats

By Naeshiro I.   Sato K.   Chatani F.   Sato S.  

European Journal of Pharmacology, Vol. 354, Iss. 2, 1998-08 ,pp. : 179-187

Elsevier

Access to resources Recommend Favorite

Pre- and postsynaptic inhibitory potencies of the angiotensin AT 1 receptor antagonists eprosartan and candesartan

By Nap A.   Mathy M.-J.   Balt J.C.   Pfaffendorf M.   van Zwieten P.A.  

European Journal of Pharmacology, Vol. 469, Iss. 1, 2003-05 ,pp. : 117-124

Elsevier

Access to resources Recommend Favorite